USA flag logo/image

An Official Website of the United States Government

CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60049
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
CA094566
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
DEKK-TEC, INC.
725 TOPAZ STREET NEW ORLEANS, LA 70124-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE
Agency: HHS
Contract: 1R43CA094566-01A1
Award Amount: $185,641.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarcoma xenograft and additional tumor xenografts of breast, lung (small cell and non-small cell) and ovary cancers. A cyclophosphamide-resistant human melanoma xenograft will also be used in order to determine the efficacy of this pre-activated form of the clinical antitumor drug ifosfamide (IFOS) in comparison with IFOS, cyclophosphamide (CPA) and 4-hydroperoxycyclophosphamide (4-HC) as a guide to possible further development of HOO-IFOS as a clinical anticancer agent. Plasma levels of chloroacetaldehyde, a metabolite of IFOS implicated as the causative agent in its neurotoxicity, and acrolein, the metabolite of IFOS and CPA that causes dose-limiting hemorrhagic cystitis, generated by HOO-IFOS vs. IFOS will be measured as an indication of comparative neurotoxic or hemorrhagic cystitic potential, resp. Possible clinical advantages of HOO-IFOS in comparison to IFOS or CPA are (1) elimination of variation in active drug administered to patients, (2) reduction or elimination of toxicities associated with IFOS or CPA and (3) possible reduction in CPA-related resistance. PROPOSED COMMERCIAL APPLICATIONS: It is possible that HOO-IFOS could become a superior clinical drug to CPA or IFOS for treating certain tumor types now treated with these two drus because of comparable/superior activity but with reduced toxicities.

Principal Investigator:

Lee R. Morgan
5044885415
LRM1579@AOL.COM

Business Contact:

Lee Morgan
5044885417
LRM1579@AOL.COM
Small Business Information at Submission:

DEKK-TEC, INC.
DEKK-TEC, INC. 4200 CANAL ST, STE A NEW ORLEANS, LA 70119

EIN/Tax ID: 720976996
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No